JPS58225074A - Dibenzoazepine derivative - Google Patents
Dibenzoazepine derivativeInfo
- Publication number
- JPS58225074A JPS58225074A JP10851682A JP10851682A JPS58225074A JP S58225074 A JPS58225074 A JP S58225074A JP 10851682 A JP10851682 A JP 10851682A JP 10851682 A JP10851682 A JP 10851682A JP S58225074 A JPS58225074 A JP S58225074A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- group
- lower alkyl
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
【発明の詳細な説明】
本発明は次の一般式
(式中、R1は水素原子又はハロゲン原子、低級アルコ
キシ基、低級アルキル基から選ばれる1〜N<R5,4
−メfルピペラジニル、4−メチルホモピペラジニル基
金意味し、R及びRはそれぞれ低級アルキル基ヌは互に
結合して窒素原子と共に複素りを形成してもよく、mは
2〜3’e示す)で表わされる化合ftt+及びその塩
に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention is based on the following general formula (wherein R1 is a hydrogen atom, a halogen atom, a lower alkoxy group, a lower alkyl group).
- methylpiperazinyl, 4-methylhomopiperazinyl group, R and R are lower alkyl groups, respectively, and may be bonded to each other to form a complex with a nitrogen atom, and m is 2 to 3'e ftt+ and its salts.
上式で表わされる本発明の化合物は、例えば、一般式
(式中R′は前記と同一の意味を有する)で表わされる
ジペンゾオキサゼピノンカルボン酸は前記と同一の意味
を有する)の化合物とを反応させることによシ答易に得
られる。ここでいう反応性該導体としては、酸ハライド
、酸無水物またはエステルなどがあげられる。The compound of the present invention represented by the above formula is, for example, a compound of the general formula (in which R' has the same meaning as above), in which dipenzoxazepinonecarboxylic acid has the same meaning as above). It can be easily obtained by reacting with a compound. Examples of the reactive conductor here include acid halides, acid anhydrides, and esters.
この反応は熱溶媒ヌはアセトン、ベンゼン、テトラヒド
ロフラン、ジオキツン、クロロホルム。This reaction uses acetone, benzene, tetrahydrofuran, dioxin, and chloroform as thermal solvents.
F[エチル、N、N−ジメチルホルムアミドなどの溶媒
あるいは水など又はその混合物中において、態で使用す
る場合には、脱水剤あるいは縮合剤の存在下で、酸ハラ
イドの状態で使用する場合には、脱ハロゲン化水素剤の
存在下または非存在下で、冷却下、室温あるいは加熱す
ることによシ行う。F [When used in a solvent such as ethyl, N, N-dimethylformamide, water, etc., or in a mixture thereof, in the presence of a dehydrating agent or a condensing agent, or in the acid halide state, , in the presence or absence of a dehydrohalogenating agent, under cooling, at room temperature, or by heating.
ここでいう脱水剤としては、たとえばN、N’−ジシク
ロへキシルカルボジイミドのようなカルボジイミドが、
縮合剤としては、たとえばオキシ塩化燐。Examples of the dehydrating agent here include carbodiimides such as N,N'-dicyclohexylcarbodiimide,
Examples of condensing agents include phosphorus oxychloride.
塩化チオニル、ホスゲンなどが、また脱ハロゲン化水素
剤としては、たとえば炭酸水素ナトリウム。Thionyl chloride, phosgene, etc., and dehydrohalogenation agents include, for example, sodium hydrogen carbonate.
炭酸水素カリウム、炭酸ナトリウム、炭酸カリウム、水
酸化ナトリウム、トリエチルアミン、ピリジンなどを使
用するのが好適である0反応時間は主に反応温度、使用
される試薬の種類によって異なるが瞬時ないし10時間
位である。It is preferable to use potassium hydrogen carbonate, sodium carbonate, potassium carbonate, sodium hydroxide, triethylamine, pyridine, etc.The reaction time varies mainly depending on the reaction temperature and the type of reagent used, but it is instantaneous to about 10 hours. be.
かくして得られる本発明の化合物は優れた抗潰瘍作用を
有し医薬として有用である。The compound of the present invention thus obtained has excellent antiulcer activity and is useful as a medicine.
実施例1゜
8−カルボキシ−2,4−ジイソプロピルジペンゾ(b
、f〕[1,4)オキサゼピン−11(IOH)オン3
.4tf乾燥ベンゼン25rIleに溶か゛し、これに
チオニルクロライド10m1’i加え3時間還流する。Example 1 8-carboxy-2,4-diisopropyldipenzo (b
, f] [1,4) Oxazepine-11 (IOH) on 3
.. 4tf was dissolved in 25ml of dry benzene, and 10ml of thionyl chloride was added thereto and refluxed for 3 hours.
反応稜、過剰のチオニルクロリド’tM圧下留去すると
、カルボン酸クロライドが油状残渣として得られる。こ
れをクロロホルム30meに溶かし、N−メチルビペラ
ジン3vと10%NaOH15*eの氷冷混合物へ攪拌
しながら滴加する。水冷下1時間そして、室温にて2時
間攪拌し、クロロホルム層を水洗4回行い、芒硝乾燥稜
溶媒を留去して、2.4−ジイソプロピルジペンゾ(b
、f)[1,4]オキサゼピン−11(IOH)オン8
−カルボン酸N−メチルピペラジンアミド3.6 f
’Iz得る。収率85.4%、ベンゼンーヘキザンから
再結晶し融点191〜2℃。10%エタノール塩酸から
融点285〜8℃(分解)の塩酸塩を得る。After the reaction, the excess thionyl chloride 'tM is distilled off under pressure to give the carboxylic acid chloride as an oily residue. This is dissolved in 30me of chloroform and added dropwise with stirring to an ice-cold mixture of 3v of N-methylbiperazine and 10% NaOH15*e. The chloroform layer was stirred for 1 hour under water cooling and then for 2 hours at room temperature, the chloroform layer was washed with water 4 times, the dry ridge solvent was distilled off, and 2,4-diisopropyldipenzo (b
, f) [1,4]oxazepine-11 (IOH) on 8
-Carboxylic acid N-methylpiperazine amide 3.6 f
'Iz get it. Yield 85.4%, recrystallized from benzene-hexane, melting point 191-2°C. A hydrochloride salt having a melting point of 285-8°C (decomposition) is obtained from 10% ethanol hydrochloric acid.
元素分析値 分子式026H3103N3としてOHN
理論値(3) 71.23 7.41 9.97実測
値に) 71.21 7.39 9.85実施例2゜
8−カルボキシジペンゾ(b、r)(1,t)オキサゼ
ピ:/−11(IOH)オン2.0 ? ’fr:乾燥
N、N−ジメチルホルムアミド35dに溶がし、トリエ
チルアミン1.1 rnlを加え、これにクロル炭酸エ
チルエステル0.94f’i−7℃で滴加する0次いで
N−メチルピペラジン0.8 mef −5℃以下で添
加し、0℃で1時間帽拌する。室綽9−夜放置した抜水
200m1に投入し、析出物をクロロ;ULAr−萱0
..”留J÷〜
去し残ffi ’eシリカゲルクロマトグラフィーに付
す。Elemental analysis value OHN as molecular formula 026H3103N3 Theoretical value (3) 71.23 7.41 9.97 Actual value) 71.21 7.39 9.85 Example 2゜8-Carboxydipenzo (b, r) ( 1,t) Oxazepi:/-11(IOH)on 2.0? 'fr: Dissolve in 35d of dry N,N-dimethylformamide, add 1.1 rnl of triethylamine, add 0.94f'i of ethyl chlorocarbonate dropwise at -7°C, then add 0.94f'i of N-methylpiperazine. Add 8 mef below -5°C and stir at 0°C for 1 hour. Muroya 9 - Pour into 200ml of drained water that was left overnight, and remove the precipitate with chloro; ULAr - 0
.. .. The residue is subjected to silica gel chromatography.
2%メタノール−クロロホルムで溶出しジペンゾ(b、
r)(x、4)オキサゼピ/−11(IOH)オンケル
ボン酸N−メチルピペラジンアミトヘゴ92得る。収率
28.7%、ベンゼン−ヘキサンから再結晶し融点20
1〜2℃、以稜、実施例1と同様にして塩酸塩を得る。Dipenzo (b,
r) (x,4)Oxazepi/-11(IOH)oncerboxylic acid N-methylpiperazine amitohego 92 is obtained. Yield 28.7%, recrystallized from benzene-hexane, melting point 20
A hydrochloride salt is obtained in the same manner as in Example 1 at 1-2°C.
融点251℃(分解)。Melting point: 251°C (decomposed).
元素分析値 分子式019I(IJO3N3としてOH
N
理論値(1) 67.46 5.68 12.46実測
値に) 67.52 5.58 12.35実施例3〜
10゜
実施例1又は実施例2と同様にして表Iの化合第1頁の
続き
Q多発 明 者 山崎保
東京都豊島区高田三丁目41番8
号中外製薬株式会社内
0発 明 者 境−成
東京都豊島区高田三丁目41番8
号中外製薬株式会社内
0発 明 者 畑俊−
東京都豊島区高田三丁目41番8
号中外製薬株式会社内
0発 明 者 高垣善男
東京都豊島区高田三丁目41番8
号中外製薬株式会社内Elemental analysis value Molecular formula 019I (OH as IJO3N3
N Theoretical value (1) 67.46 5.68 12.46 Actual value) 67.52 5.58 12.35 Example 3~
10゜ Compounds of Table I in the same manner as in Example 1 or Example 2 Continued from page 1 of Q Multiple Examples Author: Tamotsu Yamazaki Chugai Pharmaceutical Co., Ltd., 3-41-8 Takada, Toshima-ku, Tokyo 0 Inventor: Sakai - Chugai Pharmaceutical Co., Ltd., 3-41-8 Takada, Toshima-ku, Tokyo Inventor: Toshi Hata - Chugai Pharmaceutical Co., Ltd., 3-41-8 Takada, Toshima-ku, Tokyo Inventor: Yoshio Takagaki Toshima-ku, Tokyo 3-41-8 Takada Chugai Pharmaceutical Co., Ltd.
Claims (1)
キシ基、低級アルキル基から選ばれる1〜ピペラジニル
基を意味し、R4及びFLSはそれぞれ低級アルキル基
又は互に結合して窒素原子と共に複素環を形成してもよ
く、惟は2〜3を示す)で表わされる化合物及びその塩
。[Claims] General formula (wherein R1 means 1 to piperazinyl group selected from a hydrogen atom or a halogen atom, a lower alkoxy group, a lower alkyl group, and R4 and FLS are each a lower alkyl group or a bond with each other) may form a heterocycle together with a nitrogen atom, and the compound represented by the formula (2 or 3) and its salt.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10851682A JPS58225074A (en) | 1982-06-25 | 1982-06-25 | Dibenzoazepine derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10851682A JPS58225074A (en) | 1982-06-25 | 1982-06-25 | Dibenzoazepine derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS58225074A true JPS58225074A (en) | 1983-12-27 |
JPH0359068B2 JPH0359068B2 (en) | 1991-09-09 |
Family
ID=14486768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10851682A Granted JPS58225074A (en) | 1982-06-25 | 1982-06-25 | Dibenzoazepine derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS58225074A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10183936B2 (en) | 2014-03-13 | 2019-01-22 | Indiana University Research And Technology Corporation | Hepatitis B core protein allosteric modulators |
US10377748B2 (en) | 2015-09-15 | 2019-08-13 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
US10987360B2 (en) | 2016-09-15 | 2021-04-27 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
US11040965B2 (en) | 2017-03-13 | 2021-06-22 | Assembly Biosciences, Inc. | Process for making Hepatitis B core protein modulators |
US11078170B2 (en) | 2017-03-02 | 2021-08-03 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
US11649218B2 (en) * | 2018-03-09 | 2023-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same |
-
1982
- 1982-06-25 JP JP10851682A patent/JPS58225074A/en active Granted
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10183936B2 (en) | 2014-03-13 | 2019-01-22 | Indiana University Research And Technology Corporation | Hepatitis B core protein allosteric modulators |
AU2015229174B2 (en) * | 2014-03-13 | 2019-04-11 | Assembly Biosciences, Inc. | Hepatitis B core protein allosteric modulators |
US10947224B2 (en) | 2014-03-13 | 2021-03-16 | Indiana University Research And Technology Corporation | Hepatitis B core protein allosteric modulators |
US10377748B2 (en) | 2015-09-15 | 2019-08-13 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
US10392379B2 (en) | 2015-09-15 | 2019-08-27 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
US10766890B2 (en) | 2015-09-15 | 2020-09-08 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
US10968211B2 (en) | 2015-09-15 | 2021-04-06 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
US11814376B2 (en) | 2015-09-15 | 2023-11-14 | Assembly Biosciences, Inc. | Hepatitis b core protein modulators |
US10987360B2 (en) | 2016-09-15 | 2021-04-27 | Assembly Biosciences, Inc. | Hepatitis B core protein modulators |
US11078170B2 (en) | 2017-03-02 | 2021-08-03 | Assembly Biosciences, Inc. | Cyclic sulfamide compounds and methods of using same |
US11040965B2 (en) | 2017-03-13 | 2021-06-22 | Assembly Biosciences, Inc. | Process for making Hepatitis B core protein modulators |
US11649218B2 (en) * | 2018-03-09 | 2023-05-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same |
Also Published As
Publication number | Publication date |
---|---|
JPH0359068B2 (en) | 1991-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1334972C (en) | Pyridine-2,4- and -2,5-dicarboxylic acid amides, processes for their preparation, the use thereof, and medicaments based on these compounds | |
EP0249950B1 (en) | Aromatic compounds | |
EP0030009B1 (en) | New derivatives of the 9-cis-6,6'-diapo-psi,psi-carotenedioic acid, preparation thereof and pharmaceutical compositions containing same | |
JPS58225074A (en) | Dibenzoazepine derivative | |
US3751447A (en) | Novel guanidinocaproic acid phenyl esters and their production | |
WO1983000044A1 (en) | Novel aminosulfonylbenzoic acid derivatives and process for their preparation | |
JPS60231651A (en) | Manufacture of pyrrolidone derivative | |
HU182257B (en) | Process for producing benzothiazole derivatives and pharmaceutical compositions containing them as active agents | |
JPH0361667B2 (en) | ||
US3875173A (en) | Method for introducing halogen into benzimidazole and imidazopyridine compounds | |
SU505369A3 (en) | The method of obtaining the esters of 1-imidazolylmethanephosphonic acid | |
SU639450A3 (en) | Method of obtaining heterogeneous ring compounds or salts thereof | |
JPS591714B2 (en) | Process for producing isothiazoloisoquinoline derivatives | |
US2524802A (en) | Hydroxybenzenesulfonamidopyridazines and preparation of same | |
JPS606954B2 (en) | Method for producing 1-(2-tetrahydrofuryl)-3-substituted-5-fluorouracil | |
JPH03110553A (en) | Production of amidophenols | |
JPS6052158B2 (en) | Cephalosporin compounds | |
JPS6136519B2 (en) | ||
JPS58225073A (en) | Dibenzoxazepinone derivative | |
JPS5920668B2 (en) | Process for producing quinazoline derivatives | |
JPS58140065A (en) | Mercaptobenzyl fatty acid derivative and its preparation | |
US3164613A (en) | Hydroxybenzothiazoles and methods of preparing same | |
JPS5810379B2 (en) | Dipeptide Ruinoseihou | |
US3714172A (en) | Process for preparing 2-acetamido-3-benzyloxy or 3-benzylthio-pyridides and derivatives thereof | |
JPH04173780A (en) | 3,4-diphenylisoxazole derivative |